Valuation: Veru Inc.

Market Cap 49.11M 42.92M 39.41M 36.75M 69.67M 4.68B 70.85M 474M 184M 2.29B 184M 180M 7.9B P/E 2026 *
-3.01x
P/E 2027 * -3.11x
Enterprise Value 49.11M 42.92M 39.41M 36.75M 69.67M 4.68B 70.85M 474M 184M 2.29B 184M 180M 7.9B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.01%
Yield 2026 *
-
Yield 2027 * -
1 day-3.16%
1 week+4.08%
Current month-2.24%
1 month+30.21%
3 months+33.62%
6 months+34.80%
Current year+42.99%
1 week 2.99
Extreme 2.9874
3.35
1 month 2.11
Extreme 2.11
7.33
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 2016-10-30
Director of Finance/CFO 67 2012-12-31
Chief Tech/Sci/R&D Officer 64 2018-03-31
Director TitleAgeSince
Chairman 65 2018-02-28
Director/Board Member 68 2016-09-30
Director/Board Member 68 2018-02-28
Date Insider Type Main position Quantity % Market Cap.
05-03Free

Director

160,000 0.9969%
05-03Free

Director

100,000 0.6230%
05-03Free

Chief Financial Officer

164,000 1.0218%
Change 5-day change 1-year change 3-year change Capi.($)
-3.16%+4.08%-47.57%-74.29% 49.11M
-0.95%+4.18%+77.50%+133.89% 58.73B
-3.12%+3.48%+72.79%+94.67% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.68%+45.58%-1.42% 18.8B
-0.84%+9.25%+43.92%-28.29% 17.61B
+2.57%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+19.38%+42.82% - 13.9B
Average +1.76%+8.37%+43.59%+121.34% 24.22B
Weighted average by Cap. +0.96%+7.21%+57.53%+136.08%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.93M -20.14M -18.78M -35.61M -2.39B -36.21M -242M -93.98M -1.17B -94.25M -92.2M -4.04B -37.1M -32.42M -29.77M -27.76M -52.63M -3.53B -53.52M -358M -139M -1.73B -139M -136M -5.97B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
26-07-02 US$3.060 -3.16% 262,276
26-07-01 US$3.160 +0.96% 337,597
26-06-30 US$3.130 +0.32% 285,438
26-06-29 US$3.120 +3.65% 432,577
26-06-26 US$3.010 +2.38% 253,414
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.060USD
Average target price
24.50USD
Spread / Average Target
+700.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock